Regulatory press release

Active Biotech Interim Report Q3 2024

THIRD QUARTER IN BRIEF

Active Biotech entered agreement with MD Anderson for a clinical study of tasquinimod in myelofibrosis (July 1)
Active Biotech provided an update on the clinical phase Ib/IIa study with tasquinimod in relapsed refractory multiple myeloma (July 15)
Active Biotech reported intriguing intraocular concentrations achieved in a clinical biodistribution study of laquinimod eye drops (September 10)
Active Biotech announced a rights issue (September 23)

EVENTS AFTER THE END OF THE PERIOD

Active Biotech adjusts the terms in the announced rights issue (October 2)

FINANCIAL SUMMARY

SEK M	Jul-Sep		Jan-Sep		Full year
	2024 2023		2024 2023		2023
Net sales	-	-	-	-	-
Operating profit/loss	-8.1	-10.6	-29.5	-33.7	-46.5
Profit/loss after tax	-8.0	-10.6	-29.1	-33.3	-45.8
Earnings per share (SEK)	-0.02	-0.04	-0.08	-0.13	-0.17
Cash and cash equivalents (at close of period)			6.2	5.6	36.2

The report is also available at www.activebiotech.com

The information was submitted for publication, through the agency of the contact persons set out below, at 2024-10-21 22.30 CEST.

About Active Biotech

Active Biotech AB (publ) (NASDAQ Stockholm: ACTI) is a biotechnology company that develops first-in-class immunomodulatory treatments for oncology and immunology indications with a high unmet medical need and significant commercial potential. Active Biotech currently holds three projects in its portfolio, of which tasquinimod and laquinimod are wholly owned small molecule immunomodulators with a mode of action that includes modulation of myeloid immune cell function. The projects are in clinical development for hematological malignancies and inflammatory eye disorders, respectively. The company's core focus is on the development of tasquinimod in myelofibrosis, a rare blood cancer, where clinical proof-of-concept studies has been initiated. Also ongoing is a clinical Phase Ib/IIa study in multiple myeloma. Laquinimod is in clinical development for the treatment of non-infectious uveitis. A clinical phase I program with a topical ophthalmic formulation is ongoing to support phase II development together with a partner. The third pipeline project is naptumomab, a targeted anti-cancer immunotherapy, partnered to NeoTX Therapeutics, which is in a phase Ib/II clinical program in patients with advanced solid tumors. Please visit www.activebiotech.com for more information.